2022 nelson’s pediatric antimicrobial therapy twenty eighth edition
2022 Nelson’s Pediatric Antimicrobial Therapy Twenty-eighth Edition
$169.00 Original price was: $169.00.$49.00Current price is: $49.00. Add to cart
Sale!

2022 Nelson’s Pediatric Antimicrobial Therapy Twenty-eighth Edition

Original price was: $169.00.Current price is: $49.00.

-71%

Flash Sale: Any ebook for just 4.99 USD only

  • Pay with Any Debit/Credit Card
  • Affordable Prices for Readers
Guaranteed Safe Checkout

Completely updated and revised, the 28th edition of this best-selling reference provides instant access to the latest recommendations for treatment of infectious diseases in children.

For each disease, the authors provide a commentary to help select the best of all antimicrobial choices. Drug descriptions cover all antimicrobial agents available today and include complete information about dosing regimens.

TOPICS INCLUDE

Antimicrobial Therapy by Clinical Syndromes

Antimicrobial Therapy for Neonates

Choosing Among

Antibiotics

Antifungal Agents

Antiviral Agents

Antiparasitic Agents

Oral Step-down Therapy for Serious Infections

Prevention of Symptomatic Infection

Approach to Antibiotic Allergies

Antibiotic Stewardship

New in the 28th Edition

Updated recommendations on acute hematogenous osteomyelitis, based on newly published guidelines by the Pediatric Infectious Diseases Society and the Infectious Diseases Society of America, including information on a decrease in the incidence of MRSA infections, allowing the recommendation of cefazolin, again, in empiric therapy for most pediatric bone infections

Updated recommendations on influenza treatment and prophylaxis, reflecting American Academy of Pediatrics guidance for 2021–2022

Ceftazidime/avibactam now preferred over fluoroquinolones for treatment of Klebsiella pneumoniae carbapenemase–producing enteric bacilli, if susceptible

Cefiderocol, a new iron-binding siderophore cephalosporin class, recently approved in adults for treatment of many drug-resistant pathogens, particularly Acinetobacter, Stenotrophomonas, and Pseudomonas; under study in children

New dosing for posaconazole suspension formulation

New approaches to mucormycosis

Added baloxavir for children 12+ years old

Online updates of COVID-19 therapies once emergency use authorization in children at http://www.aap.org/nelsons

Updated Nelson’s app also available